Clinical Data Fuels Quintiles Buy of Consultancy
Biopharmaceutical research firm Quintiles acquisition of consulting firm Encore Health Resources is all about better collecting and understanding of clinical data to assess the safety and efficacy of drugs and measure clinical outcomes.
Biopharmaceutical research firm Quintiles acquisition of consulting firm Encore Health Resources is all about better collecting and understanding of clinical data to assess the safety and efficacy of drugs and measure clinical outcomes.
Quintiles, which operates clinical research trials and also offers market research services, expects in the second quarter to close the purchase of Encore, which offers a range of health information technology advisory services but specializes in electronic health records implementation and optimization. Terms of the deal were not disclosed.
Quintiles expects improved collection and use of clinical data will support deeper analysis of a multitude of issues related to safety and effectiveness of new treatments, says Brian Kelly, M.D., president of the companys provider and payer solutions unit. For instance, better data may help assess if a particular drug keeps a patient in remission longer and reduces readmissions, or gain insight into the cost and overall economic value of a drug. The outcome of a drug, Kelly notes, can change depending on how patients really access the drug. Active, real-world data from clinical information systems can help determine the way patients are taking drugs, as well as side effects.
As drugs get more condition-specific, Quintiles also wants to use clinical data to find the most appropriate patient populations for clinical trials, and Encore Health Resources brings that expertise. We understand providers, how they operate and how they optimize data, says CEO Dana Sellers. The consultancy knows the clinical vendors and how to capture the data in their information systems, and the acquisition by a company with the resources of Quintiles will take Encore to a higher level, she adds.
Approximately 70 percent of Encores 300 employees are clinically-certified health professionals or have advanced healthcare degrees. Now, they will have access to Quintiles 950 physicians, 900 PhDs, 600 biostatisticians and 500 nurse educators, and those professionals will have access to the clinical data pros at Encore. Combining the companies to better use data to improve measuring of treatments is right at the heart of what we do, Sellers adds. Now, Encore can accelerate its vision of driving data and value, and operate globally as it now has the infrastructure to go international.
Encore presently serves 132 healthcare organizations and Sellers insists the company wont change anything it already is doing, but will expand and also reach into life sciences. Quintiles is not too small to help us reach our vision, but not too big to get lost.
Quintiles, which operates clinical research trials and also offers market research services, expects in the second quarter to close the purchase of Encore, which offers a range of health information technology advisory services but specializes in electronic health records implementation and optimization. Terms of the deal were not disclosed.
Quintiles expects improved collection and use of clinical data will support deeper analysis of a multitude of issues related to safety and effectiveness of new treatments, says Brian Kelly, M.D., president of the companys provider and payer solutions unit. For instance, better data may help assess if a particular drug keeps a patient in remission longer and reduces readmissions, or gain insight into the cost and overall economic value of a drug. The outcome of a drug, Kelly notes, can change depending on how patients really access the drug. Active, real-world data from clinical information systems can help determine the way patients are taking drugs, as well as side effects.
As drugs get more condition-specific, Quintiles also wants to use clinical data to find the most appropriate patient populations for clinical trials, and Encore Health Resources brings that expertise. We understand providers, how they operate and how they optimize data, says CEO Dana Sellers. The consultancy knows the clinical vendors and how to capture the data in their information systems, and the acquisition by a company with the resources of Quintiles will take Encore to a higher level, she adds.
Approximately 70 percent of Encores 300 employees are clinically-certified health professionals or have advanced healthcare degrees. Now, they will have access to Quintiles 950 physicians, 900 PhDs, 600 biostatisticians and 500 nurse educators, and those professionals will have access to the clinical data pros at Encore. Combining the companies to better use data to improve measuring of treatments is right at the heart of what we do, Sellers adds. Now, Encore can accelerate its vision of driving data and value, and operate globally as it now has the infrastructure to go international.
Encore presently serves 132 healthcare organizations and Sellers insists the company wont change anything it already is doing, but will expand and also reach into life sciences. Quintiles is not too small to help us reach our vision, but not too big to get lost.
More for you
Loading data for hdm_tax_topic #better-outcomes...